eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer

eFFECTOR Therapeutics Inc EFTR, in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cancer (TNBC).
The data were at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation.
In the study, zotatifin treatment slowed tumor growth in six out of eight syngeneic TNBC models without apparent toxicity.
Zotatifin treatment was also shown to inhibit proliferative and stem cell signaling pathways and induce proteins involved in Interferon-α and Interferon-γ responses.
Additionally, the combination treatment of zotatifin with the mTOR inhibitor Novartis AG's NVS Afinitor (everolimus) demonstrated statistically significant prolonged survival compared to using these agents alone.
Related: What's Going On With eFFECTOR Therapeutics Stock Today?
Price Action: EFTR shares are up 24.7% at $14.32 during the premarket session on the last check Friday.